Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.72 Million EUR | 69.06% |
| 2022 | -18.49 Million EUR | -0.57% |
| 2021 | -18.39 Million EUR | 26.07% |
| 2020 | -24.87 Million EUR | 16.04% |
| 2019 | -29.63 Million EUR | -14.43% |
| 2018 | -25.89 Million EUR | -6.52% |
| 2017 | -24.31 Million EUR | -93.15% |
| 2016 | -12.58 Million EUR | -57.04% |
| 2015 | -8.01 Million EUR | -83.03% |
| 2014 | -4.37 Million EUR | -2404.74% |
| 2013 | 190 Thousand EUR | 100.94% |
| 2012 | -20.11 Million EUR | -57.0% |
| 2011 | -12.81 Million EUR | -168.57% |
| 2010 | -4.77 Million EUR | 61.06% |
| 2009 | -12.25 Million EUR | 51.19% |
| 2008 | -25.1 Million EUR | 46.03% |
| 2007 | -46.51 Million EUR | 11.4% |
| 2006 | -52.49 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.47 Million EUR | 0.0% |
| 2024 Q1 | - EUR | 100.0% |
| 2023 Q2 | -13.15 Million EUR | -139.61% |
| 2023 Q4 | -6.63 Million EUR | 0.0% |
| 2023 Q3 | -6.63 Million EUR | 49.56% |
| 2023 FY | -5.72 Million EUR | 69.06% |
| 2023 Q1 | 33.22 Million EUR | 270.57% |
| 2022 Q1 | 22.41 Million EUR | 221.88% |
| 2022 Q4 | -19.47 Million EUR | 0.0% |
| 2022 Q2 | -24.89 Million EUR | -211.07% |
| 2022 FY | -18.49 Million EUR | -0.57% |
| 2022 Q3 | -19.47 Million EUR | 21.77% |
| 2021 Q4 | -18.39 Million EUR | 4.61% |
| 2021 Q3 | -19.28 Million EUR | -6.54% |
| 2021 Q1 | 30.03 Million EUR | 220.72% |
| 2021 Q2 | -18.09 Million EUR | -160.26% |
| 2021 FY | -18.39 Million EUR | 26.07% |
| 2020 Q1 | 54.68 Million EUR | 284.53% |
| 2020 Q4 | -24.87 Million EUR | 4.46% |
| 2020 Q2 | -14.96 Million EUR | -127.37% |
| 2020 FY | -24.87 Million EUR | 16.04% |
| 2020 Q3 | -26.04 Million EUR | -74.02% |
| 2019 Q2 | -17.73 Million EUR | -12.29% |
| 2019 FY | -29.63 Million EUR | -14.43% |
| 2019 Q4 | -29.63 Million EUR | -144.15% |
| 2019 Q3 | -12.13 Million EUR | 31.56% |
| 2019 Q1 | -15.79 Million EUR | 39.01% |
| 2018 FY | -25.89 Million EUR | -6.52% |
| 2018 Q4 | -25.89 Million EUR | 0.02% |
| 2018 Q1 | -25.52 Million EUR | -5.0% |
| 2018 Q2 | -20.32 Million EUR | 20.39% |
| 2018 Q3 | -25.9 Million EUR | -27.45% |
| 2017 Q3 | -15.16 Million EUR | -4.29% |
| 2017 Q1 | -9.54 Million EUR | 24.14% |
| 2017 FY | -24.31 Million EUR | -93.15% |
| 2017 Q4 | -24.31 Million EUR | -60.35% |
| 2017 Q2 | -14.53 Million EUR | -52.27% |
| 2016 Q4 | -12.58 Million EUR | -151.69% |
| 2016 FY | -12.58 Million EUR | -57.04% |
| 2016 Q3 | -5 Million EUR | 50.11% |
| 2016 Q2 | -10.02 Million EUR | -31.67% |
| 2016 Q1 | -7.61 Million EUR | 5.0% |
| 2015 Q1 | -13.14 Million EUR | 12.23% |
| 2015 Q2 | -9.22 Million EUR | 29.84% |
| 2015 FY | -8.01 Million EUR | -83.03% |
| 2015 Q4 | -8.01 Million EUR | 83.96% |
| 2015 Q3 | -49.97 Million EUR | -441.94% |
| 2014 Q4 | -14.97 Million EUR | 10.26% |
| 2014 Q2 | -4.09 Million EUR | 43.26% |
| 2014 FY | -4.37 Million EUR | -2404.74% |
| 2014 Q1 | -7.22 Million EUR | 28.97% |
| 2014 Q3 | -16.68 Million EUR | -307.35% |
| 2013 Q1 | -16.67 Million EUR | 17.09% |
| 2013 FY | 190 Thousand EUR | 100.94% |
| 2013 Q3 | -11.65 Million EUR | 22.09% |
| 2013 Q2 | -14.96 Million EUR | 10.29% |
| 2013 Q4 | -10.16 Million EUR | 12.78% |
| 2012 Q3 | -22.24 Million EUR | 12.35% |
| 2012 Q1 | -10.12 Million EUR | 20.99% |
| 2012 FY | -20.11 Million EUR | -57.0% |
| 2012 Q4 | -20.11 Million EUR | 9.58% |
| 2012 Q2 | -25.37 Million EUR | -150.7% |
| 2011 FY | -12.81 Million EUR | -168.57% |
| 2011 Q1 | -18.8 Million EUR | -294.15% |
| 2011 Q2 | -15.86 Million EUR | 15.64% |
| 2011 Q3 | -15.37 Million EUR | 3.04% |
| 2011 Q4 | -12.81 Million EUR | 16.69% |
| 2010 FY | -4.77 Million EUR | 61.06% |
| 2010 Q4 | -4.77 Million EUR | 55.76% |
| 2010 Q3 | -10.78 Million EUR | -31.49% |
| 2010 Q2 | -8.2 Million EUR | -0.23% |
| 2010 Q1 | -8.18 Million EUR | 33.22% |
| 2009 FY | -12.25 Million EUR | 51.19% |
| 2009 Q4 | -12.25 Million EUR | 0.0% |
| 2008 FY | -25.1 Million EUR | 46.03% |
| 2007 FY | -46.51 Million EUR | 11.4% |
| 2006 FY | -52.49 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 99.95% |
| CureVac N.V. | -360.92 Million EUR | 98.414% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 101.002% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 101.002% |
| BRAIN Biotech AG | -693 Thousand EUR | -725.974% |
| Formycon AG | 2.45 Million EUR | 333.537% |
| Heidelberg Pharma AG | -37.6 Million EUR | 84.78% |